A double-blind, controlled trial to evaluate the efficacy and safety of vitamin K1 ointment for cetuximab and Panitumumab-induced acneiform eruption

Interventions: 0.1% vitamin K1 ointment twice daily
Placebo ointment twice daily
Primary outcome(s): The number of acneiform eruptions of right and left lesions(face, neck, or chest) of the same patient before and after treatment
Study Design: Parallel Randomized

干预措施：0.1%维生素K1（vitamin K1）软膏，每日两次；安慰剂软膏，每日两次。
主要结局指标：同一患者治疗前后，其面部、颈部或胸部左右侧皮损的痤疮样皮疹（acneiform eruptions）数量。
研究设计：平行随机试验。